| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6916802 | GENZYME CORP | Amino ceramide-like compounds and therapeutic methods of use |
Apr, 2022
(1 year, 4 months ago) | |
| US7196205 | GENZYME CORP | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Jun, 2026
(2 years from now) | |
| US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615573 | GENZYME CORP | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Apr, 2022
(1 year, 4 months ago) | |
| US7253185 | GENZYME CORP | Amino ceramide-like compounds and therapeutic methods of use |
Apr, 2022
(1 year, 4 months ago) | |
| US10888547 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Jan, 2031
(7 years from now) | |
| US10888544 | GENZYME CORP | Methods for treating Gaucher disease |
Dec, 2038
(15 years from now) | |
Cerdelga is owned by Genzyme Corp.
Cerdelga contains Eliglustat Tartrate.
Cerdelga has a total of 7 drug patents out of which 3 drug patents have expired.
Expired drug patents of Cerdelga are:
- US7615573
- US7253185
- US6916802
Cerdelga was authorised for market use on 19 August, 2014.
Cerdelga is available in capsule;oral dosage forms.
Cerdelga can be used as long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day), long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with mild hepatic impairment and are concurrently taking a strong or moderate cyp3a inhibitor, treatment of gaucher disease type 1.
The generics of Cerdelga are possible to be released after 13 December, 2038.
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
Market Authorisation Date: 19 August, 2014
Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat ...
Dosage: CAPSULE;ORAL
CERDELGA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic